BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Proximagen Neuroscience plc (PRX.L) Signs to Acquire Cambridge Biotechnology from Biovitrum AB


10/22/2009 8:16:54 AM

Bookmark and Share

Proximagen Neuroscience plc, and Biovitrum AB announce that they have signed a letter of intent for Proximagen to acquire Biovitrum’s wholly-owned subsidiary Cambridge Biotechnology Limited for a percentage of future revenues generated from CBT’s pipeline. CBT’s clinical stage projects consist of 5-HT2C agonists and 5-HT6 antagonists and its pre-clinical stage projects include VAP-1 and Trk A programmes. It is expected that completion will take place by mid November.

For further information, please contact:

Proximagen Neuroscience plc Kenneth Mulvany, Chief Executive Officer James Hunter, Finance Director Phone: +44 (0)20 7848 6938

Buchanan Communications Tim Anderson, Catherine Breen Phone: +44 (0)20 7466 5000

Evolution Securities Limited (NOMAD) Stuart Andrews, Bobbie Hilliam Phone: +44 (0)20 7071 4300

About Proximagen Neuroscience

Proximagen is a biopharmaceutical company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system. Its current lead programmes aim to improve the quality of life for patients suffering from neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

The Company raised £50 million to pursue its strategy to acquire a number of the exciting drug programmes and commercial prospects in its preferred therapeutic area of the central nervous system that have become available at attractive valuations.

Proximagen has already developed a broad pipeline of partnered and unpartnered drug candidate programmes to address the significant unmet medical needs of patients with neurodegenerative disease.

Proximagen joined the AIM market of the London Stock Exchange in March 2005. For more information please visit the Company’s web site: www.proximagen.com.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES